Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli

Abstract Background Individuals with impaired immunity are more susceptible to infections than immunocompetent subjects. No vaccines are currently available to induce protection against E. coli meningoencephalitis. This study evaluated the potential of poly(I:C) pre-treatment to induce trained immun...

Full description

Bibliographic Details
Main Authors: Sandra Ribes, Christa Arcilla, Martina Ott, Sandra Schütze, Uwe-Karsten Hanisch, Stefan Nessler, Roland Nau
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Journal of Neuroinflammation
Subjects:
Online Access:https://doi.org/10.1186/s12974-020-1700-4
id doaj-58b990a2c32f4be48615a3382e7be1ae
record_format Article
spelling doaj-58b990a2c32f4be48615a3382e7be1ae2021-01-17T12:16:58ZengBMCJournal of Neuroinflammation1742-20942020-01-0117111010.1186/s12974-020-1700-4Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coliSandra Ribes0Christa Arcilla1Martina Ott2Sandra Schütze3Uwe-Karsten Hanisch4Stefan Nessler5Roland Nau6Institute of Neuropathology, University Medical Center GöttingenInstitute of Neuropathology, University Medical Center GöttingenInstitute of Neuropathology, University Medical Center GöttingenInstitute of Neuropathology, University Medical Center GöttingenInstitute of Neuropathology, University Medical Center GöttingenInstitute of Neuropathology, University Medical Center GöttingenInstitute of Neuropathology, University Medical Center GöttingenAbstract Background Individuals with impaired immunity are more susceptible to infections than immunocompetent subjects. No vaccines are currently available to induce protection against E. coli meningoencephalitis. This study evaluated the potential of poly(I:C) pre-treatment to induce trained immunity. Poly(I:C) was administered as a non-specific stimulus of innate immune responses to protect immunocompetent and neutropenic wild-type mice from a subsequent challenge by the intracranial injection of E. coli K1. Methods Three days prior to infection, mice received an intraperitoneal injection of poly(I:C) or vehicle. Kaplan-Meier survival curves were analyzed. In short-term experiments, bacterial titers and the inflammatory response were characterized in the blood, cerebellum, and spleen homogenates. NK cell subpopulations in the brain and spleen were analyzed by flow cytometry. Numbers of microglia and activation scores were evaluated by histopathology. Results Pre-treatment with 200 μg poly(I:C) increased survival time, reduced mortality, and enhanced bacterial clearance in the blood, cerebellum, and spleen at early infection in neutropenic mice. Poly(I:C)-mediated protection correlated with an augmented number of NK cells (CD45+NK1.1+CD3−) and Iba-1+ microglial cells and a higher production of IFN-γ in the brain. In the spleen, levels of CCL5/RANTES and IFN-γ were increased and sustained in surviving poly(I:C)-treated animals for 14 days after infection. In immunocompetent animals, survival time was not significantly prolonged in poly(I:C)-treated animals although poly(I:C) priming reduced brain bacterial concentrations compared with vehicle-injected animals at early infection. Conclusions Pre-treatment with the viral TLR3 agonist poly(I:C) modulated innate immune responses and strengthened the resistance of neutropenic mice against E. coli K1 meningoencephalitis.https://doi.org/10.1186/s12974-020-1700-4MeningitisPoly(I:C)Trained innate immunityNK cellMicrogliaIFN-γ
collection DOAJ
language English
format Article
sources DOAJ
author Sandra Ribes
Christa Arcilla
Martina Ott
Sandra Schütze
Uwe-Karsten Hanisch
Stefan Nessler
Roland Nau
spellingShingle Sandra Ribes
Christa Arcilla
Martina Ott
Sandra Schütze
Uwe-Karsten Hanisch
Stefan Nessler
Roland Nau
Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli
Journal of Neuroinflammation
Meningitis
Poly(I:C)
Trained innate immunity
NK cell
Microglia
IFN-γ
author_facet Sandra Ribes
Christa Arcilla
Martina Ott
Sandra Schütze
Uwe-Karsten Hanisch
Stefan Nessler
Roland Nau
author_sort Sandra Ribes
title Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli
title_short Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli
title_full Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli
title_fullStr Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli
title_full_unstemmed Pre-treatment with the viral Toll-like receptor 3 agonist poly(I:C) modulates innate immunity and protects neutropenic mice infected intracerebrally with Escherichia coli
title_sort pre-treatment with the viral toll-like receptor 3 agonist poly(i:c) modulates innate immunity and protects neutropenic mice infected intracerebrally with escherichia coli
publisher BMC
series Journal of Neuroinflammation
issn 1742-2094
publishDate 2020-01-01
description Abstract Background Individuals with impaired immunity are more susceptible to infections than immunocompetent subjects. No vaccines are currently available to induce protection against E. coli meningoencephalitis. This study evaluated the potential of poly(I:C) pre-treatment to induce trained immunity. Poly(I:C) was administered as a non-specific stimulus of innate immune responses to protect immunocompetent and neutropenic wild-type mice from a subsequent challenge by the intracranial injection of E. coli K1. Methods Three days prior to infection, mice received an intraperitoneal injection of poly(I:C) or vehicle. Kaplan-Meier survival curves were analyzed. In short-term experiments, bacterial titers and the inflammatory response were characterized in the blood, cerebellum, and spleen homogenates. NK cell subpopulations in the brain and spleen were analyzed by flow cytometry. Numbers of microglia and activation scores were evaluated by histopathology. Results Pre-treatment with 200 μg poly(I:C) increased survival time, reduced mortality, and enhanced bacterial clearance in the blood, cerebellum, and spleen at early infection in neutropenic mice. Poly(I:C)-mediated protection correlated with an augmented number of NK cells (CD45+NK1.1+CD3−) and Iba-1+ microglial cells and a higher production of IFN-γ in the brain. In the spleen, levels of CCL5/RANTES and IFN-γ were increased and sustained in surviving poly(I:C)-treated animals for 14 days after infection. In immunocompetent animals, survival time was not significantly prolonged in poly(I:C)-treated animals although poly(I:C) priming reduced brain bacterial concentrations compared with vehicle-injected animals at early infection. Conclusions Pre-treatment with the viral TLR3 agonist poly(I:C) modulated innate immune responses and strengthened the resistance of neutropenic mice against E. coli K1 meningoencephalitis.
topic Meningitis
Poly(I:C)
Trained innate immunity
NK cell
Microglia
IFN-γ
url https://doi.org/10.1186/s12974-020-1700-4
work_keys_str_mv AT sandraribes pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
AT christaarcilla pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
AT martinaott pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
AT sandraschutze pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
AT uwekarstenhanisch pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
AT stefannessler pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
AT rolandnau pretreatmentwiththeviraltolllikereceptor3agonistpolyicmodulatesinnateimmunityandprotectsneutropenicmiceinfectedintracerebrallywithescherichiacoli
_version_ 1724335126091923456